<DOC>
	<DOCNO>NCT01823198</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose immune cell call natural killer ( NK ) cell give chemotherapy stem cell transplant patient AML MDS . Researchers want learn add NK cell help make stem cell transplant effective treating disease . The safety treatment also study .</brief_summary>
	<brief_title>Natural Killer ( NK ) Cells With HLA Compatible Hematopoietic Transplantation High Risk Myeloid Malignancies</brief_title>
	<detailed_description>Central Venous Catheter : If choose take part study , chemotherapy , drug study , NK cell , stem cell transplant give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein local anesthesia . Blood sample also draw CVC . The CVC remain body treatment . Your doctor explain procedure detail , require sign separate consent form . NK Cell Dose Levels : You assign dose level NK cell base join study . Up 4 dose level NK cell test . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose NK cell find . Chemotherapy , NK Cell infusion , Stem Cell Transplant : For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . You receive dose busulfan vein 3 hour outpatient within 2 week hospital admission inpatient Day -15 . With first busulfan infusion , 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test various time point receive first dose busulfan . The study staff tell blood test schedule . PK test measure amount study drug body different time point . The PK test help doctor decide dose busulfan Days -13 -10 . A heparin lock line place vein low number needle stick need draws . If possible PK test perform , receive standard dose busulfan . On Days -13 -10 , receive fludarabine vein 1 hour , busulfan vein 3 hour . On Day -9 , rest . On Day -8 , receive NK cell vein 1 hour . On Days -8 -4 , receive IL-2 injection skin . On Day -3 , rest . Beginning Day -2 , receive tacrolimus nonstop vein . This continue able take mouth . Tacrolimus give help prevent transplant rejection . On Day 0 , receive stem cell transplant vein . On Days +1 , +3 , +6 , +11 , receive methotrexate vein 30 minute . Methotrexate give help prevent graft versus host disease ( GVHD ) . When able take tacrolimus mouth , take 1 time 2 time day 6 month doctor tell taper ( gradually stop take ) . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : On Day -7 -5 , blood ( 5 tablespoon time ) drawn check level infuse NK cell check immune system . If receive NK cell match sibling , blood ( 5 tablespoon ) also draw Day +7 test . After finish chemotherapy cell infusion , follow-up care standard care stem cell transplant . Before able go home hospital , give write information taught often come hospital/clinic , take drug home , side effect may . The study staff also stay contact local doctor find disease come back check . Length Study : You active study +30 day . You may take study early disease get bad , unable receive NK cell infusion due product contamination insufficient cell dose , transplant `` take '' ( graft failure ) , intolerable side effect , unable follow study direction , doctor think best interest , study stop , choose leave study early . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . If think drop study , please tell study doctor . The doctor tell effect stop treatment . You doctor talk follow-up care test would help . If leave study , test result information remove study record . This investigational study . Busulfan , fludarabine , IL-2 FDA approve commercially available treatment type cancer . Their use treatment AML MDS investigational . The use NK cell investigational . The NK cell process FDA approve commercially available . It currently use research purpose . Up 72 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients age &lt; /= 65 year one following : 2 . Acute myeloid leukemia fail achieve complete remission one course induction chemotherapy relapse . Patients must less 20 % bone marrow peripheral blood blast . 3 . Acute myeloid leukemia first remission follow high risk feature define : ( ) Adverse cytogenetics : 5 , del 5q , 7 , del7q , abnormality involve 3q , 9q , 11q , 20q , 21q , 17 , +8 complex karyotype [ &gt; 3 abnormality ] ( ii ) Preceding myelodysplastic myeloproliferative syndrome ; ( iii ) Presence high risk molecular abnormality include FLT3 mutation , DNMT3A , TET2 ; ra ; kit ; ( iv ) FAB M6 M7 classification ; ( v ) treatmentrelated AML . ( vi ) residual cytogenetic molecular abnormality 4 . Myelodysplastic syndrome intermediate , high high risk RIPSS score , CMML therapy relate MDS . 5 . CML : ( ) fail achieve cytogenetic remission tyrosine kinase inhibitor treatment cytogenetic relapse ; ( ii ) ever accelerate phase blast crisis . 6 . Patient must identify HLA ( A , B , C , DR ) compatible relate unrelated donor age 16 year age old weighs least 110 pound stem cell donation . 7 . Zubrod performance status 0 2 Karnofsky least 60 . 8 . Left ventricular ejection fraction &gt; /= 45 % . No uncontrolled arrhythmia uncontrolled symptomatic cardiac disease . 9 . FEV1 , FVC DLCO &gt; /= 50 % expect , correct hemoglobin . 10 . Adequate liver function : a. Bilirubin &lt; /= 1.5 mg/dl ( unless Gilbert 's syndrome ) . b. SGPT &lt; /= 200 IU/ml unless related patient malignancy . c. Hepatitis B surface antigen negative hepatitis C antibody negative . d. No evidence chronic active hepatitis cirrhosis . e. Patients history hepatitis C , negative viral load , eligible . f. The protocol chairman determine eligibility patient related hepatic abnormality . 11 . Serum creatinine &lt; 1.5 mg % . 12 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . Patients age 7 &lt; 18 provide assent . 13 . Pediatric patient ( age 718 year ) enter 3 adult patient enter without dose limit toxicity . 1 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . The Protocol PI final arbiter eligibility . 2 . Pleural/pericardial effusion ascites &gt; 1L . 3 . Patients know HIVseropositive . 4 . Pregnancy : Positive pregnancy test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 5 . Women child bear potential willing use effective contraceptive measure study . 6 . Patients know allergy mouse protein .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>High Risk Myeloid Malignancies</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>Natural Killer Cells</keyword>
	<keyword>NK</keyword>
	<keyword>Immune cell</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>ATG</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Methotrexate</keyword>
</DOC>